Ultragenyx Pharmaceutical Obtains $75,000,000 Series B Round

  • Feed Type
  • Date
    12/20/2012
  • Company Name
    Ultragenyx Pharmaceutical
  • Mailing Address
    77 Digital Drive Novato, CA 94949
  • Company Description
    Ultragenyx is a new startup focused on developing therapeutics for rare diseases. The company is lead by Emil Kakkis, M.D., Ph.D., former CMO of BioMarin Pharmaceutical, and will build on management’s experience in choosing and developing products with clear mechanisms of action in untreated rare diseases.
  • Website
    http://www.ultragenyx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $75,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The company will use the proceeds to advance development of its meaning clinical stage programs, UX001 and UX003, as well as other undisclosed programs.
  • M&A Terms
  • Venture Investor
    Adage Capital Management
  • Venture Investor
    TPG Biotech
  • Venture Investor
    T. Rowe Price
  • Venture Investor
    BlackRock
  • Venture Investor
    Sanofi
  • Venture Investor
    Shire Pharmaceuticals
  • Venture Investor
    Fidelity BioSciences
  • Venture Investor
    Healthcap Venture Capital
  • Venture Investor
    Pappas Ventures

By posting a comment, you agree to our terms and conditions.